Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547365 · ClinicalTrials.gov registry record · Phase 1
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
A Phase 1 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00547365 is a Phase 1 study that has completed, run by University of Tennessee. The registered enrollment target is 10 participants.
The verdict
NCT00547365, a Phase 1 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread. Others find abnormal cells and help kill them or carry cell-killing substances to them. Giving human immune globulin may be effective in treating patients with primary amyloidosis that is causing heart dysfunction. PURPOSE: This phase I/II trial is studying the side effects and best dose of human immune globulin and to see how well it works in treating patients with primary amyloidosis that is causing heart dysfunction.
Interventions
- BIOLOGICAL Human immune globulin intravenous (IGIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547365
The ClinicalTrials.gov registry entry for NCT00547365 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human immune globulin intravenous (IGIV) is the first listed.
NCT00547365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547365 about?
NCT00547365 is a clinical study titled "Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction". RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread. Others find abnormal cells and help kill them or carry cell-killing substances to them. Giving human immune globulin may be eff...
What is the current status of trial NCT00547365?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00547365?
The interventions under investigation include: Human immune globulin intravenous (IGIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00547365?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.